About Us

Meet the team behind Sensill's novel skin infection diagnosis.

Our Story

Sensill is developing a novel diagnostic technology system based on a proven approach to sensing skin/wound infection by identifying & quantifying the bacterial & fungal pathogens that cause it.

What we are doing

Sensill is developing a method of diagnosing skin/wound infections that is fundamentally different than standard methods. We're working on this to help doctors provide a greater degree of accuracy in diagnosis at the point of care when making a decision to treat an infection, while striving to enable them to monitor the patient's response to therapy.

How we are doing it

Volatile organic compounds (VOCs) are emitted by all living organisms including bacteria & fungi. Just like dogs are capable of picking up minute amounts of VOCs by simply smelling, we aim to capture & detect VOCs emitted by bacteria & fungi. Sensill is developing proprietary technology to identify & quantify the VOCs emitted by infectious microorganisms causing skin & wound infections.


CEO Image

Ardeshir Bayat, CEO

A results-driven, cross-functional, & passionate leader in innovation strategy, executing change & product development, bringing 25+ years of clinical (MD), scientific (PhD) & industry expertise in successfully contributing to Sensill's growth & development from the ground-up. Leveraging experience as a translational skin scientist (with significant academic background) in all phases of R&D (laboratory & clinical), business strategy, marketing & product development. Internationally recognized expert in skin healing with an H-index of 74 having overseen an active multi-disciplinary research laboratory capable of performing in silico, in vitro, ex vivo & in vivo clinical trials. Previous recipient of many competitive awards, including the Medical Research Council (MRC) Clinical Training Fellowship Award & the National Institute for Health Research (NIHR) Clinician Scientist Award.
CEO Image


years of experience


publications in scientific journals


presentations worldwide

Ardeshir Bayat

Mitch Levinson, Executive Chair

Mitchell E. Levinson joined Dr. Bayat as Sensill's Executive Chair when the company was in its formative stage. He is Chief Strategy Officer of Pulse Biosciences, where he joined the Board of Directors in 2015. Mr. Levinson has over 30 years of experience developing & launching novel medical device technologies across multiple medical disciplines. He co-founded & served as startup CEO for Cerebrotech Medical Systems where he led the development of a novel brain monitor. Mr. Levinson was the first employee & startup CEO for Zeltiq Aesthetics, the CoolSculpting company, acquired by Allergan in 2017. Prior to Zeltiq, he held executive R&D positions at Thermage & BioSurgical Corporation & previous product development positions at Nellcor (Medtronic), Baxter, & HP. Mr. Levinson currently sits on the boards of directors for several medical technology startup companies. He is an inventor on over 50 issued & numerous pending U.S. patents. Mr. Levinson earned his B.S. in Mechanical Engineering from University of California at San Diego & holds an M.S. in Computer Systems from the University of Phoenix.


years in diagnostic devices


billion in acquisitions

Michael Sinsheimer, Investor & Strategic Advisor

Mr. Sinsheimer is the founder of Medtech Catalyst, which has founded or co-founded several medical & dental device companies. He currently advises several medical technology companies including Sensill. He is co-founder & Chairman of Mobius Imaging, LLC as well as the co-founder & CEO of Cardan Robotics which were acquired by Stryker in 2019 for an aggregate purchase price of $500M. Prior to that, Mr. Sinsheimer has had various key management roles as President of Integrated Marketing Concepts, a consulting firm advising healthcare product companies; VP of Marketing & Strategic Planning for the Straumann Company, a dental implant company that grew to several hundred million in revenue; & Marketing Manager at Pfizer, Inc. Mike holds an MHA from the University of North Carolina Gillings School of Global Public Health & an MBA from the Stern School of Graduate Business at New York University.


years of healthcare experience


billion in acquisitions

Bill Shea, VP of R&D and Operations

Bill Shea has held various roles in manufacturing, technical service, research, and engineering/product development of advanced medical technology. With over 6 years as Vice President of R&D & Operations at Cerebrotech Medical Systems, he led the organization's efforts in engineering, research, patenting, manufacturing, and product development of neurotechnology solutions. Cerebrotech developed a novel non-invasive wireless neurological device for quick stroke assessment. Before joining Cerebrotech in 2015, Mr. Shea served as VP of R&D at Clarity Medical Systems, where he led the organization's engineering, research, patenting, and product development efforts in advanced ophthalmic applications. Clarity introduced groundbreaking technology for premature babies' blindness & improved refractive outcomes in cataract surgery. Prior to joining Clarity in 2005, Mr. Shea was employed at Nellcor, the world leader in pulse oximetry. At Nellcor, Mr. Shea served roles of increasing responsibility with his last role being the head of the Pulse Oximetry Hardware Group where he led the development of an advanced form of pulse oximetry to meet market demands for low power consumption, miniaturization, and improved performance. Mr. Shea holds a B.S. in Electrical Engineering & Computer Science from UC, Berkeley.


years of experience in medtech


filed US & international patent offices

Scientific Advisory